SubsidieMeestersChronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Projectdetails
Introduction
About 25% of the adult population experiences chronic pain, which disrupts daily activities and severely affects the patient’s quality of life. In Europe, the socioeconomic burden of chronic pain runs into billions of euros annually and represents 3–10% of the GDP.
Current Treatment Limitations
The current mainstays of pain treatment are non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. However, their prolonged use is frequently associated with life-threatening adverse events and physical dependence. There is therefore an urgent need for new pharmacological strategies with superior efficacy and safety than those of NSAIDs and opioids.
Project Overview
PAIN-CARE proposes to address chronic pain signaling using inhibitors targeting the Schwann cell proalgesic pathway. Previous research has shown the crucial role of Schwann cells in sustaining chronic pain.
Objectives
This project aims at developing Schwann cell selective drugs for chronic pain treatment, creating more clinically ready compounds based on bifunctional chimeric antagonists, with an inhibitory activity 100% higher than that of the combination of the two individual antagonists in mouse chronic pain models.
Expected Outcomes
The new Schwann Cell selective Analgesic Drugs (SCADs) will provide a dramatic change in the pain treatment paradigm, reducing treatment-related side effects and improving persistence.
Methodology
During this PoC, we aim to identify lead bifunctional chimeric molecules that preferentially antagonise two Schwann cell proteins.
Testing
We will carry out tests in vitro and in vivo to demonstrate the novel compounds’ feasibility and superior inhibition efficiency when compared to the currently used compounds.
Commercialisation Strategy
Furthermore, our aim is to translate the results to a pre-commercialisation phase through the definition of the innovation commercial feasibility and potential, which will then be validated in discussions with relevant market players.
IPR Strategy
A strong IPR strategy will be designed to ensure an advantageous position in the value chain of analgesics for pain treatment.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-11-2023 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCSpenvoerder
- UNIVERSITA DEGLI STUDI DI FIRENZE
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Descending control of painDescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies. | ERC ADG | € 2.500.000 | 2023 | Details |
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAINPersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients. | ERC COG | € 1.618.278 | 2023 | Details |
Uncovering the cortical cellular basis of specificity and chronicity of painThis project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief. | ERC ADG | € 2.468.700 | 2025 | Details |
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic painSea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment. | EIC Accelerator | € 2.499.035 | 2024 | Details |
Descending control of pain
DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN
PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.
Uncovering the cortical cellular basis of specificity and chronicity of pain
This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.